AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

Launched by ·

Keywords

ClinConnect Summary

This clinical trial is studying a new combination of medicines called bemarituzimab and bevacizumab to treat three types of gynecological cancers: cancer of the uterus lining (endometrial cancer), ovary, and cervix. The main goal is to find the safest dose of bemarituzimab when given with a fixed amount of bevacizumab and to see how well this combination works in these cancers.

Women between the ages of 65 and 74 who have one of these cancers might be eligible to join the study. Participants will receive both medicines and be closely monitored to check for side effects and to see if the treatment is helping to control their cancer. It’s important to know that this study is still in the early stages and is not yet open for enrolling patients.

Gender

FEMALE

Eligibility criteria